BACKGROUND The genetic cause of hypertrophic cardiomyopathy remains unexplained in a substantial proportion of
Ochoa et al.
Of the probands, 3,189 had a diagnosis of HCM. An additional 2,777 index cases with no evidence of structural cardiac disease (mainly channelopathies and aortic diseases) were used as control subjects.
The predominant ethnicity was European (>90% of the probands), and there were no differences between HCM probands and control subjects. The variants' frequencies in the general population were extracted from the gnomAD database version r2.0, August 2017 (6).
In the initial screening phase, candidate variants in Bioinformatics analysis was performed by means of a custom pipeline including software for variant calling, genotyping, and annotation.
To establish the pathogenicity of identified variants, we developed a customized classification scheme based on the recommendations of the American College of Medical Genetics and Genomics (Online Table 2 ) (8) were excluded from this analysis).
FHOD3 is an HCM-Causing Gene Ochoa et al. Table 4 ). Table 5 ). The presentation was familial (at least 1 affected family member) in 25 families (83%), and 5 cases (17%) were sporadic (there was no family history, and none of the evaluated relatives were affected).
After clinical evaluation and genotyping of 129 members from 25 families, a final combined LOD score of 7.92 was obtained, equivalent to a p value <3 Â 10 À7 , indicative of very strong cosegregation (Online Table 6 ) (9). A total of 13 variants were considered pathogenic or very likely pathogenic; in all of them, there was evidence of cosegregation with HCM in at least 1 family (Online Table 7 ). Disease-causing variants were distributed in 35 HCM probands without additional variants that could explain the disease in sarcomeric genes, The p.Tyr528Cys variant in FHOD3 was identified independently in 4 index cases belonging to 4 nuclear subfamilies (arrows) from the same region of Murcia, Spain.
A subsequent genealogic analysis determined that they were descendants of a common ancestor born 7 generations ago. (95% CI: 6.9 to 28.7; p < 0.001). The complete list of the pathogenic or likely pathogenic variants and the distribution along the FHOD3 protein is summarized in Figure 3A . The variants identified in control subjects or in phenotypes other than HCM were randomly distributed throughout the gene, but none of them was identified in the coiled-coil domain or affecting residues 527 to 528 (Online Figure 1) .
Only 2 truncating variants in FHOD3 were identified in HCM cases: p.Lys1433Serfs*10 and p.Arg1597*.
Both were present at very low frequencies in control subjects (MAF% 0.002 and 0.0004, respectively). The p.Lys1433Serfs*10 variant was identified in a patient who carried an additional variant, p.Arg17Gln, in MYBPC3; although it was excluded from the analysis, segregation was evaluated in the family, but the results were inconclusive (Online Figure 2) at age 70 years, 15% of men and 32% of women were clinically unaffected ( Figure 4A ). Figure 2) . The other 7 were relatives in whom genetic testing was unavailable. Two patients (2 of 13; 15%) experienced heart failure death: a 58-year-old woman who had a concomitant diagnosis of rheumatic severe mitral stenosis and a 37-year-old man with a restrictive filling pattern.
DISCUSSION
In this study, we demonstrated a clear relationship between FHOD3 mutations and the development of HCM (Central Illustration). Almost 7,800 probands were screened for the presence of very rare candidate variants in FHOD3, and an excess of these variants in the HCM cohort with respect to control subjects was observed (OR: 3). This ratio is lower than those obtained by other groups using the same approach for nontruncating variants in MYBPC3 (OR: 5.7) or MYH7 (OR: 12) (7), reflecting that not all of the very rare candidate variants in FHOD3 are necessarily associated with disease. As in other sarcomeric genes, it is difficult to predict if a novel nontruncating variant is pathogenic or not; in these cases, segregation analysis in the family is mandatory. In our study, The phenotype associated with FHOD3 mutations in our study was relatively mild, with a low rate of adverse events in young individuals and an overall rate of cardiovascular endpoints similar to that described in unselected HCM patient cohorts (12, 13) .
Two-thirds of the index cases were men, and the diagnosis in female carriers was made 10 years later than in males. Late onset of the disease and incomplete penetrance were observed in both sexes.
The association between FHOD3 and HCM has been postulated in a GWAS study (5 STUDY LIMITATIONS. One of the limitations of our study is that segregation was limited in some families because of the small number of relatives available for screening, and clinical assessment was incomplete in some carriers. Another possible limitation is that patients were screened only for genes previously associated with inherited cardiac conditions; therefore, the presence of mutations in other genes contributing to the phenotype cannot be ruled out. 
CONCLUSIONS

